Abstract
Background:
Cystatin C (CysC) is often used to diagnose and monitor renal diseases. Although some studies have investigated the association between serum CysC levels and thyroid diseases, their reported results were inconsistent. Therefore, the relationship between CysC levels and thyroid diseases remains controversial.
Aim:
This meta-analysis aimed to statistically evaluate serum CysC levels in patients with thyroid diseases.
Methods:
A literature search was conducted using the PubMed, Web of Science, Embase, EBSCO, and Wiley Online Library databases. The following search terms were used for the title or abstract: “Cystatin C” or “CysC” in combination with the terms “thyroid disease”, “thyroid function”, “hypothyroidism”, or “hyperthyroidism”. The results of the systematic analysis were presented as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs).
Results:
Eleven articles (1,265 cases and 894 controls) were included in the meta-analysis. The results of the meta-analysis showed that the serum CysC levels of patients with hyperthyroidism were significantly higher than those of the controls (SMD: 1.79, 95% CI [1.34, 2.25]), and the serum CysC levels of patients with hypothyroidism were significantly lower than those of the controls (SMD −0.59, 95% CI [−0.82, −0.36]). Moreover, the treatment of thyroid diseases significantly affected serum CysC levels.
Conclusions:
To the best of our knowledge, this meta-analysis is the first to evaluate serum CysC levels in patients with thyroid diseases. Our findings suggest that thyroid function affects serum CysC levels and that serum CysC may be an effective marker for monitoring thyroid diseases.
Systematic Review Registration:
PROSPERO [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=258022], identifier CRD42021258022].
Introduction
Cystatin C (CysC), a small-molecule protein belonging to the cysteine protease inhibitor superfamily, is produced by all nucleated cells. Compared with serum creatinine, changes in CysC levels can sensitively reflect changes in the glomerular filtration rate (GFR). Therefore, it is often used in the diagnosis and evaluation of kidney diseases (1). Studies have shown that serum CysC is a sensitive biomarker for detecting changes in GFR and identifying mild kidney diseases (2, 3). Moreover, patients with diabetes, chronic obstructive pulmonary disease, ischemic stroke, and myocardial infarction have been reported to have higher serum CysC levels than healthy individuals (4–7).
Thyroid diseases, including hyperthyroidism and hypothyroidism, are common endocrine system diseases. Thyroid hormones have a great influence on renal hemodynamics, water–salt balance, ion transport, renal tubular secretion, and reabsorption (8). Few studies have investigated the association between serum CysC levels and thyroid diseases. Some authors reported that the serum CysC levels of patients with hyperthyroidism and hypothyroidism were higher and lower, respectively, although the results were inconsistent (9–11). Therefore, the relationship between serum CysC levels and thyroid diseases remains controversial. This meta-analysis aimed to statistically evaluate serum CysC levels in patients with thyroid diseases. In addition, we used serum CysC levels for treatment monitoring.
Methods
Search
We searched the following electronic databases: Web of Science, Embase, PubMed, EBSCO, and Wiley Online Library databases. The following search terms were used for the title or abstract: “Cystatin C” or “CysC” in combination with the terms “thyroid disease”, “thyroid function”, “hypothyroidism”, or “hyperthyroidism”. All studies published between 1980 and 2021 were included in the search. In addition, the references of the retrieved articles were examined to identify additional eligible studies, excluding unpublished studies. The completed Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist is presented in Supplementary Data (Table S1). This systematic review and meta-analysis was registered in PROSPERO (registration number: CRD42021258022).
Inclusion Criteria
The studies included in this meta-analysis met the following criteria: (1) a case–control or cohort design; (2) detailed data about serum CysC levels in patients with thyroid disease and controls; and (3) published in English.
Data Extraction and Risk of Bias
Two researchers independently extracted general information from the included articles, such as the first author, publication year, study period, region, study design, and details of cases and controls. The Newcastle–Ottawa Scale is a risk assessment tool for observational studies recommended by the Cochrane Collaboration (12, 13). Quality of evidence was also assessed using the Grade of Recommendations Assessment, Development, and Evaluation (GRADE) approach (14). The two researchers independently assessed the studies through discussion, compared their findings, and resolved any differences by consensus. If no consensus was reached, a third researcher resolved the difference.
Statistical Analysis
The results of the systematic analysis were presented as standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs). Heterogeneity among studies was assessed using Cochran’s Q test and I2 statistic. I2 of <50% was considered to have low or moderate heterogeneity, and a fixed-effects model was used. Otherwise, heterogeneity was considered high, and a random-effects model was used for the analysis. We additionally performed a sensitivity analysis to evaluate the influence of any given study on the pooled estimate. Publication bias was evaluated using Egger’s test. A P-value of <0.05 was considered to indicate statistical significance. All statistical analyses were performed using Stata version 12.0 (College Station, TX, USA).
Results
In total, 298 studies were retrieved from the PubMed, Web of Science, Embase, EBSCO, and Wiley Online Library databases. No articles from the reference lists were included in this study. After screening, 11 articles comprising 1,265 cases and 894 controls were selected (9, 15–24). The inclusion criteria for full-text selection are presented in Figure 1. The characteristics of the selected studies are summarized in Table 1.
Figure 1
Flowchart of the detailed procedure for the inclusion or exclusion of selected studies.
Table 1
| Author | Publication Year | Study Period | Region | Study design | Cystatin C level | Case factor | |
|---|---|---|---|---|---|---|---|
| Case | Control | ||||||
| Fricker M | 2003 | 2000 – 2002 | Switzerland | Prospective study | hyperthyroidism (before treatment): 1.32 ± 0.17; hypothyroidism (before treatment): 0.84 ± 0.17 | hyperthyroidism (after treatment): 0.95 ± 0.19; hypothyroidism (after treatment): 1.1 ± 0.28 | Patients with newly diagnosed hypo- or hyperthyroidism who had been referred to the Hospital. Hypothyroidism: nine cases. Median age (range) at diagnosis was 34 (14-52) years. hyperthyroidism: thirteen cases. The median age (range) at diagnosis was 43 (22 to 86) years. |
| Wiesli P | 2003 | 2000 – 2003 | Switzerland | Prospective study | hyperthyroidism (before treatment): 1.04 ± 0.29; hypothyroidism (before treatment): 0.88 ± 0.23 | hyperthyroidism (after treatment): 0.92 ± 0.25; hypothyroidism (after treatment): 1.01 ± 0.21 | Patients with mild thyroid dysfunction who had been referred to the Hospital. Twenty-six patients with subclinical hypothyroidism were included. Median (range) age at diagnosis was 42 (14–78) years. Fourteen patients with subclinical hyperthyroidism were included. The median age (range) at diagnosis was 43 (22–78) years. |
| Manetti L | 2005 | 2003 | Italy | Case-control study | hyperthyroidism: 0.9 ± 0.24; hypothyroidism: 0.69 ± 0.17 | 0.81 ± 0.17 | 58 patients with untreated Graves’ disease (47 females and 11 males; 41 ± 13 years) and 20 patients with subclinical hypothyroidism (16 females and 4 males; 37 ± 13 years) were enrolled. The control group had 5 healthy subjects (3 females and 2 males) with age of 41 ± 15 years. |
| Goede DL | 2009 | 1998 – 2016 | Switzerland | Prospective study | 0.79 ± 0.27 | 1.03 ± 0.42 | Sixteen Patients with newly diagnosed primary and central hypothyroidism were included in the study. Mean age at diagnosis was 44 ± 18 years. All patients were treated with levothyroxine for 4 ± 2 months. |
| Özden TA | 2010 | July 2012 – April 2013 | Turkey | Case-control study | 0.6 ± 0.1 | 0.67 ± 0.1 | A total of 25 patients with permanent congenital hypothyroidism were included in the study group. Twenty-one age-matched healthy children formed the control group. |
| Kotajima N | 2010 | 2003 – 2005 | Japan | Case-control and prospective study | hyperthyroidism: 0.950 ± 0.188; hypothyroidism: 0.655 ± 0.243 | control: 0.732 ± 0.008; hyperthyroidism (after treatment): 0.77 ± 0.17 | Thirty-three patients with untreated Graves’ disease (24 females and nine males; 43.7 ± 16.5 years) and eight patients with untreated hypothyroidism (seven females and one male; 52.2 ± 20.6 years) were enrolled. The control group had 25 healthy subjects (17 females and eight males) with age of 41.2 ± 10.2 years. |
| Stojanoski S | 2011 | January 2007 – December 2009 | Turkey | Case-control and Prospective study | hyperthyroidism (before treatment): 1.65 ± 0.5; hypothyroidism (before treatment): 0.88 ± 0.7 | control: 0.85 ± 0.14; hyperthyroidism (after treatment): 0.96 ± 0.5; hypothyroidism (after treatment): 1.24 ± 0.5 | Thirty-five consecutive patients (26 females and 9 males; 43 ± 11 years) were enrolled in the study. The study group included: 20 patients (14 females and 6 males) with newly diagnosed hypothyroidism and 15 patients (12 females and 3 males) with newly diagnosed hyperthyroidism. Thirty-five age- and sex-matched normal subjects served as controls. |
| Kimmel M | 2012 | – | Germany | Prospective study | hyperthyroidism (before treatment): 1.07 ± 0.21; hypothyroidism (before treatment): 0.8 ± 0.09 | hyperthyroidism (after treatment): 0.82 ± 0.08; hypothyroidism (after treatment): 0.88 ± 0.09 | Hypothyroidism: nine cases (3 females and 6 males; 42 ± 14 years). hyperthyroidism: seven cases (6 females and 1 male; 46 ± 11 years). |
| Suzuki Y | 2015 | March 2013 – September 2014 | Japan | Case-control and Prospective study | hyperthyroidism: 1.06 ± 0.20; hyperthyroidism (before treatment): 0.99 ± 0.17 | control: 0.82 ± 0.08; hyperthyroidism (after treatment): 0.75 ± 0.06 | 113 patients with untreated or poorly controlled Graves’ disease (89 females and 24 males; 44.9 ± 14.8 years). The control group had 146 age-matched healthy volunteers subjects (100 females and 46 males) with age of 49.2 ± 18.1 years. |
| Al Musaimi O | 2019 | – | Saudi Arabia | Case-control study | hyperthyroidism: 4.14 ± 2.69; hypothyroidism: 0.60 ± 0.46 | 1.15 ± 0.40 | 9 patients with thyroid hypothyroidism (four cases) and hyperthyroidism (five cases) dysfunctions (6 females and 1 male) with an age interval of (28–61) years. The control group had 16 healthy subjects (3 females and 13 males) with median age (range) was 43 (22–78) years. |
| Can N | 2020 | – | Turkey | Case-control study | 1.35 ± 0.22 | 0.74 ± 0.09 | Thirty patients with Graves’ disease (13 females and 17 males; 36.1 ± 18.4 years). The control group had 30 healthy subjects (14 females and 16 males) with age of 34.0 ± 10.1 years. |
Study characteristics of the published studies included in the meta-analysis.
Results of the Meta-Analysis
The results of the meta-analysis revealed that the serum CysC levels of patients with hyperthyroidism were significantly higher than those of the controls (SMD: 1.79, 95% CI [1.34, 2.25]). The forest plots and funnel plots of serum CysC levels of patients with hyperthyroidism compared with those of controls are presented in Figure 2. The serum CysC levels of patients with hypothyroidism were significantly lower than those of the controls [SMD −0.59, 95% CI (−0.82, −0.36)]. The forest plots and funnel plots of serum CysC levels of patients with hypothyroidism compared with those of controls are presented in Figure 3.
Figure 2
Forest plots and funnel plots of serum CysC in patients with hyperthyroidism compared with controls. Diamond represents the SMDs at 95% CI. (A) Forest plots; (B) Funnel plots. CysC, Cystatin C; SMD, standardized mean difference; CI, confidence interval.
Figure 3
Forest plots and funnel plots of serum CysC in patients with hypothyroidism compared with controls. Diamond represents the pooled SMDs at 95% CI. (A) Forest plots; (B) Funnel plots. CysC, Cystatin C; SMD, standardized mean difference; CI, confidence interval.
Sensitivity Analysis, Publication Bias, and Quality of Evidence
A sensitivity analysis was performed to examine the influence of each study. We found no significant difference between the results of the sensitivity analysis and our previous estimates, indicating that our statistical results were relatively credible (Figure 4). Articles obtained from the databases were carefully and comprehensively searched. Egger’s test was also conducted to determine whether potential publication bias existed in the reviewed literature. While no publication bias was observed in the hyperthyroidism group (P > 0.05), some publication bias might have existed in the hypothyroidism group (P < 0.05). Using the approach recommended by the GRADE system, the certainty of the evidence for studies in the meta-analysis was evaluated as low or very low.
Figure 4
The sensitivity analysis results of serum CysC in patients with hyperthyroidism and hypothyroidism compared with controls. (A) Hyperthyroidism; (B) Hypothyroidism. CysC, Cystatin C.
Discussion
This meta-analysis evaluated the serum CysC levels of patients with thyroid diseases. Although some studies have investigated the association between serum CysC levels and thyroid diseases, their results were inconsistent. In this meta-analysis, 11 independent studies were included and analyzed. We concluded that the serum CysC levels of patients with hyperthyroidism and those with hypothyroidism were significantly higher and lower than those of the controls, respectively. The treatment of thyroid diseases also significantly affected the serum CysC levels, making CysC a potentially effective marker for monitoring the treatment of thyroid diseases.
CysC is a nonglycosylated protein with 120 amino acid residues. CysC production is more stable than creatinine production and is not affected by inflammation, bilirubin, and triglycerides, as well as sex, age, muscle mass, or diet. CysC, owing to its small molecular weight and positive charge, can freely pass through the glomerular filtration membrane and is almost completely reabsorbed in the proximal convoluted tubules. After reabsorption, it is completely catabolized and no longer returns to the blood circulation. Further, CysC is not secreted by the renal tubules and its production rate in the tissue is constant (1, 25). The kidney is the only organ that clears CysC in circulation. Blood CysC levels are determined by glomerular filtration, and inter-individual differences are small. The difference between the highest value in the population and the normal average value was <3–4 standard deviations. CysC is a new index that can reflect GFR with high specificity, good accuracy, and sensitivity compared with the creatinine clearance rate. It is an ideal endogenous marker that reflects the changes in GFR (26, 27).
Fricker et al. reported that an increase in the thyroid hormone content in the blood of patients with hyperthyroidism can promote the synthesis of Na+ - K+ - ATPase in many cells of the body, increase the basal metabolic rate and oxygen consumption, accelerate the cell renewal rate/metabolic rate, and promote the secretion of CysC by nucleated cells, thereby accelerating the production rate of CysC. Under the condition of normal renal function, the increase in serum CysC levels in patients with hyperthyroidism is not caused by renal injury but is related to increased basal metabolic rate and oxygen consumption (15).
Studies have shown that the serum transforming growth factor-β1 (TGF-β1) levels are significantly increased in patients with Graves’ disease and that there is a positive correlation between TGF-β1 and thyroid hormone levels. In addition, TGF-β1 levels decreased in patients with Graves’ disease after treatment. Studies have also reported that serum TGF-β1 levels in patients with hypothyroidism were significantly decreased. TGF-β1 stimulates vascular smooth muscle cells to secrete CysC. In vivo, TGF-β1 stimulated the secretion of CysC and increased the expression of CysC mRNA in HepG2 cells. Notably, T3 stimulated Hep-G2 cells to produce CysC in a dose-dependent manner (19). TGF-β1 treatment has been shown to upregulate CysC transcription in mouse embryonic cells and 3T3-L1 fibroblasts (28–30). Schmid et al. used a T3-responsive osteoblast cell line to investigate whether T3 stimulates the production of CysC in vitro and reported that T3 increased the expression and accumulation of CysC mRNA in the culture medium in a dose- and time-dependent manner. It was considered that the increased production of CysC induced by T3 may be related to an increased demand for cell metabolism and proteolysis control (31).
In our study, we noted that even mild thyroid dysfunction (subclinical hyperthyroidism/hypothyroidism) affected the serum CysC levels of patients. Due to the limited number of reports (only one paper) on subclinical thyroid diseases, we could not perform subgroup analysis. Thus, more studies on serum CysC levels and subclinical thyroid diseases are warranted.
Strengths and Limitations
This meta-analysis firstly aimed to statistically evaluate serum CysC levels in patients with thyroid diseases. However, this study has some limitations. Due to the lack of case-control studies with a large sample population, most studies included in this meta-analysis were studies with a small sample population. Further, some studies did not use healthy controls controlled for body mass index. Different CysC detection methods were used among the studies, and the heterogeneity among studies on hyperthyroidism was high, partly due to different severities of hyperthyroidism being analyzed. These factors may have affected our results. Therefore, the results obtained herein should be interpreted cautiously, as further research is needed.
Conclusion
To the best of our knowledge, this meta-analysis is the first to evaluate serum CysC levels in patients with thyroid diseases. Our findings suggest that thyroid function affects serum CysC levels and that serum CysC may be an effective marker to monitor the treatment of thyroid diseases. More high-quality studies are needed to better support the association between serum CysC levels and thyroid diseases.
Funding
This research was financially supported by the Natural Science Foundation of Jiangsu Province (grant No. SBK2020040002).
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
Author contributions
XS designed the study. BS and XS searched databases and collected the data. HF and JX assessed the quality of the study. XS performed the analysis. HF and JX wrote the manuscript. All authors contributed to the article and approved the submitted version.
Acknowledgments
We thank Enago for English-language editing.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2021.766516/full#supplementary-material
Supplementary Table 1Preferred reporting items for systematic review and meta-analyses (PRISMA) checklist.
Supplementary Table 2Full electronic search strategy for Pubmed.
References
1
AbrahamsonMOlafssonIPalsdottirAUlvsbäckMLundwallAJenssonOet al. Structure and Expression of the Human Cystatin C Gene. Biochem J (1990) 268:287–94. doi: 10.1042/bj2680287
2
DharnidharkaVRKwonCStevensG. Serum Cystatin C Is Superior to Serum Creatinine as a Marker of Kidney Function: A Meta-Analysis. Am J Kidney Dis (2002) 40(2):221–6. doi: 10.1053/ajkd.2002.34487
3
LaterzaOFPriceCPScottMG. Cystatin C: An Improved Estimator of Glomerular Filtration Rate? Clin Chem (2002) 48(5):699–707. doi: 10.1093/clinchem/48.5.699
4
BiMHuangZLiPChengCHuangYChenW. The Association Between Elevated Cystatin C Levels With Myocardial Infarction: A Meta-Analysis. Int J Clin Exp Med (2015) 8(11):20540–7.
5
WangYLiWYangJZhangMTianCEMaMet al. Association Between Cystatin C and the Risk of Ischemic Stroke: A Systematic Review and Meta-Analysis. J Mol Neurosci (2019) 69(3):444–9. doi: 10.1007/s12031-019-01373-1
6
MaCDuanCHuangRTangH. Association of Circulating Cystatin C Levels With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Arch Med Sci (2020) 16(3):648–56. doi: 10.5114/aoms.2019.83511
7
ChaiLFengWZhaiCShiWWangJYanXet al. The Association Between Cystatin C and COPD: A Meta-Analysis and Systematic Review. BMC PULM Med (2020) 20(1):1–11. doi: 10.1186/s12890-020-01208-5
8
SimeoniMCerantonioAPastoreILiguoriRGrecoMFotiDet al. The Correct Renal Function Evaluation in Patients With Thyroid Dysfunction. J Endocrinol Invest (2016) 39(5):495–507. doi: 10.1007/s40618-015-0402-8
9
WiesliPSchweglerBSpinasGASchmidC. Serum Cystatin C Is Sensitive to Small Changes in Thyroid Function. Clin Chim Acta (2003) 338(1-2):87–90. doi: 10.1016/j.cccn.2003.07.022
10
YeYGaiXXieHJiaoLZhangS. Impact of Thyroid Function on Serum Cystatin C and Estimated Glomerular Filtration Rate: A Cross-Sectional Study. Endocr Pract (2013) 19(3):397–403. doi: 10.4158/EP12282.OR
11
SuzukiYMatsushitaKSeimiyaMYoshidaTSawabeYOgawaMet al. Paradoxical Effects of Thyroid Function on Glomerular Filtration Rate Estimated From Serum Creatinine or Standardized Cystatin C in Patients With Japanese Graves’ Disease. Clin Chim Acta (2015) 451(Pt B):316–22. doi: 10.1016/j.cca.2015.10.018
12
WellsGASheaBO’ConnellDPetersonJWelchVLososMet al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (Accessed 2014 Aug 5).
13
HigginsJPTGreenS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available at: http://www.cochrane-handbook.org (Accessed 2014 Aug).
14
Grading Quality of Evidence and Strength of Recommendations in Clinical Practice Guidelines. Part 1 of 3. An Overview of the GRADE Approach and Grading Quality of Evidence About Interventions – Pubmed [Internet]. (Accessed 2020 Jul 7).
15
FrickerMWiesliPBrandleMSchweglerBSchmidC. Impact of Thyroid Dysfunction on Serum Cystatin C. Kidney Int (2003) 63(5):1944–7. doi: 10.1046/j.1523-1755.2003.00925.x
16
ManettiLPardiniEGenovesiMCampomoriAGrassoLMorselliLLet al. Thyroid Function Differently Affects Serum Cystatin C and Creatinine Concentrations. J Endocrinol Invest (2005) 28(4):346–9. doi: 10.1007/BF03347201
17
GoedeDLWiesliPBrändleMBestmannLBernaysRLZwimpferCet al. Effects of Thyroxine Replacement on Serum Creatinine and Cystatin C in Patients With Primary and Central Hypothyroidism. SWISS Med WKLY (2009) 139(23-24):339–44.
18
ÖzdenTA. Effect of Hypo-and Euthyroid Status on Serum Cystatin C Levels-Original Article. J Clin Res Pediatr E (2010) 2(4):155–8. doi: 10.4274/jcrpe.v2i4.155
19
KotajimaNYanagawaYAokiTTsunekawaKMorimuraTOgiwaraTet al. Influence of Thyroid Hormones and Transforming Growth Factor-Beta1 on Cystatin C Concentrations. J Int Med Res (2010) 38(4):1365–73. doi: 10.1177/147323001003800418
20
StojanoskiSGjorcevaDPGruevTRistevska-MicevaSRistevskaN. Impact of Thyroid Dysfunction on Serum Cystatin C, Serum Creatinine and Glomerular Filtration Rate. Macedonian J Med Sci (2011) 15; 4(1):25–30. doi: 10.4158/EP12282.OR
21
KimmelMBraunNAlscherMD. Influence of Thyroid Function on Different Kidney Function Tests. Kidney Blood Pressure Res (2012) 35(1):9–17. doi: 10.1159/000329354
22
SuzukiYMatsushitaKSeimiyaMYoshidaTSawabeYOgawaMet al. Paradoxical Effects of Thyroid Function on Glomerular Filtration Rate Estimated From Serum Creatinine or Standardized Cystatin C in Patients With Japanese Graves’ Disease. Clin Chim Acta (2015) 451:316–22. doi: 10.1016/j.cca.2015.10.018
23
Al MusaimiOAbu-NawwasAHAl ShaerDKhaleelNYFawziM. Influence of Age, Gender, Smoking, Diabetes, Thyroid and Cardiac Dysfunctions on Cystatin C Biomarker. Medicina Familia SEMERGEN (2019) 45(1):44–51. doi: 10.1016/j.semerg.2018.07.005
24
CanNOzsoyEKobatSGYusufogluEIlhanNDemirT. Serum Cystatin C Concentrations in Patients With Graves’ Ophthalmopathy. Korean J Ophthalmol (2020) 34(5):398–403. doi: 10.3341/kjo.2020.0006
25
MussapMPlebaniM. Biochemistry and Clinical Role of Human Cystatin C. Crit Rev Clin Lab Sci (2004) 41:467–550. doi: 10.1080/10408360490504934
26
CollEBoteyAAlvarezLPochEQuintoLSaurinaAet al. Serum Cystatin C as a New Marker for Noninvasive Estimation of Glomerular Filtration Rate and as a Marker for Early Renal Impairment. Am J Kidney Dis (2000) 36:29–34. doi: 10.1053/ajkd.2000.8237
27
AstorBCLeveyASStevensLAVan LenteFSelvinECoreshJ. Method of Glomerular Filtration Rate Estimation Affects Prediction of Mortality Risk. J Am Soc Nephrol (2009) 20:2214–22. doi: 10.1681/ASN.2008090980
28
SolemMRawsonCLindburgKBarnesD. Transforming Growth Factor β Regulates Cystatin C in Serum-Free Mouse Embryo (SFME) Cells. Biochem Biophys Res Commun (1990) 172:945–51. doi: 10.1016/0006-291X(90)90767-H
29
AfonsoSTovarCRomagnanoLBabiarzB. Control and Expression of Cystatin C by Mouse Decidual Cultures. Mol Reprod Dev (2002) 61:155–163. doi: 10.1002/mrd.1142
30
SokolJPSchiemannWP. Cystatin C Antagonizes Transforming Growth Factor β Signaling in Normal and Cancer Cells. Mol Cancer Res (2004) 2:183–195.
31
SchmidCGhirlanda-KellerCZwimpferCZoidisE. Triiodothyronine Stimulates Cystatin C Production in Bone Cells. Biochem BIOPH Res CO (2012) 419(2):425–30. doi: 10.1016/j.bbrc.2012.02.040
Summary
Keywords
cystatin C, CysC, thyroid disease, systematic review, meta-analysis
Citation
Xin C, Xie J, Fan H, Sun X and Shi B (2021) Association Between Serum Cystatin C and Thyroid Diseases: A Systematic Review and Meta-Analysis. Front. Endocrinol. 12:766516. doi: 10.3389/fendo.2021.766516
Received
29 August 2021
Accepted
23 October 2021
Published
19 November 2021
Volume
12 - 2021
Edited by
Marco António Campinho, Universidade do Algarve, Portugal
Reviewed by
Sebastjan Bevc, Maribor University Medical Centre, Slovenia; Vahidreza Ostadmohammadi, Kashan University of Medical Sciences, Iran
Updates
Copyright
© 2021 Xin, Xie, Fan, Sun and Shi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xin Sun, sunxin77@126.com; Bimin Shi, shibimin@163.com
†These authors have contributed equally to this work
This article was submitted to Thyroid Endocrinology, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.